Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

NCT ID: NCT02933944

Last Updated: 2022-01-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2019-09-30

Brief Summary

The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the checkpoint inhibitor pembrolizumab (Part II), in patients with locally advanced primary and recurrent colorectal cancer scheduled to have surgery.

Part I will include 4-6 patients and Part II will include up to 10 patients. Part I and Part II are separate and independent sequential components of the study. Patients will only be able to participate in either the Part I cohort or Part II cohort.

Main objective of the study is to investigate safety and immune response after TG02-treatment.

Conditions

Rectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TG02-treatment

Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).

Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered.

Group Type: EXPERIMENTAL

TG02-treatment

Intervention Type: BIOLOGICAL

Pembrolizumab

Intervention Type: DRUG

Interventions

TG02-treatment

Intervention Type: BIOLOGICAL

Pembrolizumab

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with locally advanced primary and recurrent colorectal cancer (CRC) (histologically or cytologically confirmed adenocarcinoma), with a confirmed oncogenic KRAS exon 2, codon 12 or 13 mutations, eligible for radical pelvic surgery at time of enrolment.
• Patient is ≥18 years of age and able to consent
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• Patient has adequate organ and bone marrow function within 28 days of study

• Neutrophil count >1.5 x10^9/L
• Platelets >100 x10^9/L
• Hb >90g/L
• Total bilirubin <1.5 upper limit of normal, ULN
• ALT and AST <3.0 x ULN
• Serum creatinine <3 x ULN or Creatinine Clearance ≥ 30ml/min (Cockroft-Gault or Nuclear GFR method)
• PT and APTT <1.3 x ULN
• The patient is willing and able to comply with the protocol, and agrees to return to the hospital for study visits and examinations
• Men and women of childbearing potential must use adequate contraception to prevent pregnancy during the study. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care. An adequate contraception includes hormonal contraception with implants or combined oral, transdermal or injectable contraceptives, certain intrauterine devices, bilateral tubal ligation, hysterectomy, or vasectomy of partner. A combination of male condom with either cap, diaphragm or sponge with spermicide are also considered acceptable. For women of childbearing potential a negative pregnancy test needs to be confirmed before inclusion.
• The patient has been fully informed about the study and is willing to participate in the study, and has provided written informed consent form prior to any trial specific screening procedures.

Exclusion Criteria

• The patient has previously received an anticancer vaccine or immune checkpoint inhibitor, or participated in a trial involving the use of an anticancer vaccine or immune checkpoint inhibitor
• Patients where pre-surgery radiotherapy, chemotherapy or other anti-cancer therapy has not been completed ≥ 2 weeks prior to TG02-treatment
• The patients is receiving anti-cancer therapy for concurrent illness
• The patient has had a prior different malignancy within the last 3 years (excluding adequately treated basal cell or squamous cell carcinoma of the skin cancer, or localised low grade tumours considered cured and not requiring systemic therapy)
• The patient has uncontrolled or significant intercurrent or recent illness including:

• auto-immune disorder or history of autoimmune disease requiring immunosuppressive treatment.
• cardiac disorder such as uncontrolled cardiac failure, unstable angina or non-ST segment elevation myocardial infarction (NSTEMI) or myocardial infarction, uncontrolled arrhythmia less than 3 months before screening
• stroke or thromboembolic event within 3 months of study commencement
• active or uncontrolled severe infection
• history of solid organ transplantation or any condition requiring chronic treatment with corticosteroids or other immunosuppressive agents
• active coagulopathy/bleeding diathesis
• cirrhosis, chronic active or untreated persistent hepatitis
• history of adverse reactions to peptide vaccines
• The patient is pregnant or lactating.
• Has received an investigational drug within 4 weeks prior to study drug administration, or unless other has been agreed with the medical monitor
• Is currently receiving any agent with a known effect on the immune system, unless at dose levels that are not immunosuppressive (e.g. prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma)
• Known history of positive tests for HIV/AIDS
• Are planned to receive yellow fever or other live (attenuated) vaccines during the course of study
• For Part II - any contraindication to receiving pembrolizumab:

If using the 50 mg lyophilized powder; hypersensitivity to the active substance (pembrolizumab) or to any of the excipients; L-histidine, L-histidine hydrochloride monohydrate, Sucrose, Polysorbate 80.

If using the 100 mg concentrate; hypersensitivity to the active substance (pembrolizumab) or to any of the excipients; L-histidine, Sucrose, Polysorbate 80

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Targovax ASA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Royal Brisbane & Women's Hospital (RBWH)

Brisbane, , Australia

Peter MacCallum Cancer Centre

Melbourne, , Australia

Auckland City Hospital

Auckland, , New Zealand

Christchurch Hospital

Christchurch, , New Zealand

Countries

Australia; New Zealand

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CT TG02-01

Identifier Type: -

Identifier Source: org_study_id